A 2023 IDSA guidance recommended against the use of ertapenem in critically ill patients as well those with hypoalbuminemia. The latter is based on PK data indicating rapid clearance of of the free fraction of the drug, which has approximately 90% protein binding, resulting in lack of attainment of ...